NCT04020510 is a Phase 4 clinical trial of onaBoNT-A in Overactive Bladder, sponsored by Walter Reed National Military Medical Center.

Who is sponsoring NCT04020510?

NCT04020510 is sponsored by Walter Reed National Military Medical Center.

What drugs are being tested in NCT04020510?

Interventions in NCT04020510: onaBoNT-A.

What condition does NCT04020510 study?

NCT04020510 studies Overactive Bladder.

Is NCT04020510 still recruiting?

NCT04020510 is currently recruiting now. Last updated 28 April 2020.

Last reviewed 2020-04-28 · How we verify

NCT04020510

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder

Recruiting now Phase 4 Last updated 28 April 2020

What this trial tests

Phase 4 trial testing onaBoNT-A in Overactive Bladder in 184 participants. Currently enrolling.

Timeline

1 July 2019

Primary endpoint
1 July 2021

31 December 2021

Quick facts

Lead sponsor	Walter Reed National Military Medical Center
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	184
Start date	1 July 2019
Primary completion	1 July 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

onaBoNT-A — full drug profile →

Conditions studied

Overactive Bladder — all drugs for Overactive Bladder →

Sponsor

Walter Reed National Military Medical Center

Who can join

18 and older, any sex, with Overactive Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

OnabotulinumtoxinA is an effective treatment for both idiopathic and neurogenic overactive bladder and was FDA approved for this indication in 2013. The standard technique for injecting onabotulinumtoxinA into the detrusor is mixing 100 units of onabotulinumtoxinA into 10mL of injectable normal saline and injecting 20 sites with 0.5mL in the posterior wall of hte bladder for idiopathic overactive bladder and mixing 200 units into 30mL and injecting 30 sites with 1mL for neurogenic overactive bladder. The purpose of this study is to compare the efficacy of a technique using a reduced number of injections with the same dosage of onabotulinumtoxinA to the standard technique. The hypothesis is that the reduced technique will not be inferior in terms of efficacy as the standard technique and that there will be a lower incidence of urinary tract infections and urinary retention requiring catheterization post-procedure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder.
DiCarlo-Meacham AM, Dengler KL, Welch EK, Brooks DI, et al · · 2023 · cited 14× · PMID 36455284 · DOI 10.1002/nau.25107

Verify or expand the search:

Other trials of onaBoNT-A

Trials testing the same drug.

NCT06101160 — Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy · completed

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting

Other Walter Reed National Military Medical Center trials

Trials by the same sponsor.

NCT07151417 — Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. · Phase 2, PHASE3 · not yet recruiting
NCT06636136 — Transtibial Osseointegration · NA · recruiting
NCT06808347 — Difference in Serum Estrogen Level Based on Methods of Vaginal Estrogen Application (fingertip Vs Applicator Use) in Pos · Phase 4 · not yet recruiting
NCT06731348 — Patient Satisfaction With Opioid Restriction After Urogynecologic Surgery · Phase 4 · enrolling by invitation
NCT06729151 — Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patient · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04020510 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Walter Reed National Military Medical Center
Last refreshed: 28 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04020510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing